Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.
Irish Examiner on MSN8h
Profits fall by 27% at Abbvie's Botox plant at WestportUse precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...
According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...
Chicago Tribune on MSN14d
UChicago Medicine receives $75M donation for new cancer hospitalUniversity of Chicago Medicine has received a $75 million donation from the AbbVie Foundation to help it build its massive ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback